Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) have received an average recommendation of “Moderate Buy” from the ten research firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $24.00.

Several analysts recently commented on the stock. HC Wainwright reissued a “buy” rating and set a $32.00 target price on shares of Iovance Biotherapeutics in a research note on Monday, August 12th. JMP Securities cut their target price on shares of Iovance Biotherapeutics from $25.00 to $23.00 and set a “market outperform” rating for the company in a research note on Thursday, June 20th. Piper Sandler downgraded shares of Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $19.00 to $10.00 in a research report on Monday, July 29th. Finally, StockNews.com upgraded shares of Iovance Biotherapeutics to a “sell” rating in a research report on Monday, August 12th.

Institutional Investors Weigh In On Iovance Biotherapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. ORG Partners LLC purchased a new stake in Iovance Biotherapeutics in the 2nd quarter worth approximately $32,000. Quest Partners LLC lifted its position in Iovance Biotherapeutics by 1,237.7% in the 2nd quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock worth $40,000 after buying an additional 4,629 shares in the last quarter. Quadrant Capital Group LLC lifted its position in Iovance Biotherapeutics by 1,227.8% in the 4th quarter. Quadrant Capital Group LLC now owns 5,059 shares of the biotechnology company’s stock worth $41,000 after buying an additional 4,678 shares in the last quarter. Fidelis Capital Partners LLC purchased a new stake in Iovance Biotherapeutics in the 1st quarter worth approximately $87,000. Finally, EverSource Wealth Advisors LLC purchased a new stake in Iovance Biotherapeutics in the 2nd quarter worth approximately $58,000. Hedge funds and other institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Price Performance

Iovance Biotherapeutics stock opened at $11.38 on Friday. The firm has a 50 day simple moving average of $9.07 and a 200-day simple moving average of $11.11. The stock has a market capitalization of $3.18 billion, a PE ratio of -6.32 and a beta of 0.63. Iovance Biotherapeutics has a 12-month low of $3.21 and a 12-month high of $18.33.

Iovance Biotherapeutics (NASDAQ:IOVA) last released its earnings results on Thursday, August 8th. The biotechnology company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.01. Iovance Biotherapeutics had a negative net margin of 23,615.70% and a negative return on equity of 71.45%. The business had revenue of $31.11 million during the quarter, compared to analyst estimates of $24.59 million. During the same period in the prior year, the business earned ($0.47) earnings per share. The business’s quarterly revenue was up 12969.7% on a year-over-year basis. On average, analysts forecast that Iovance Biotherapeutics will post -1.39 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.